Compare 8x8 Inc (EGHT) vs 10X Genomics Inc (TXG) Price & Performance

EGHT trades at $2.13, down 0.47% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth with $715M in 2025 and positive earnings beats in recent quarters, though profitability remains challenged with a net loss of $27M. Recent news highlights cost-saving customer implementations and AI platform growth, while analyst consensus is mixed with a $19.77 price target representing significant upside potential.

EGHT presents a high-risk, high-reward opportunity with substantial analyst upside but faces execution risks amid competitive pressures. The stock's current valuation at 72x P/E reflects growth expectations, but investors must weigh the company's debt load and margin challenges against its strategic positioning in cloud communications and AI innovation.

TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.

The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.